United States: ‘Country Of Origin’ Compliance: The Top 10 Things Pharmaceutical Companies Need To Know

Last Updated: February 10 2014
Article by Jeffrey Orenstein

What is the "country of origin" for the drugs you manufacture? This question arises every time a pharmaceutical company labels a drug, imports it, exports it, markets it, or sells it to the U.S. government. Unfortunately, the answer to this question is more complicated than many think. In fact, the correct answer often changes, depending on which government agency is asking.

Here are the Top 10 things pharmaceutical companies need to know before determining their products' country of origin (hereinafter "COO"):

1. A drug's COO often varies under different agencies' COO standards

U.S. Customs law requires all drugs to be marked with their COO (unless they are U.S.-made). For this purpose, a product's COO is the country where its various components are "substantially transformed" into a new product with a different character and use. But, as discussed below, a different COO standard may apply when determining a product's eligibility for government procurement. A higher standard applies for "Made in the USA" claims. And, when foreign trading partners request a "certificate of origin" for goods exported to their country, COO standards vary by country of export and category of goods.

2. A drug's COO for Customs-marking purposes is usually the COO of its API

Customs views the active pharmaceutical ingredient ("API") as the "essence" of any pharmaceutical product and, even though raw API must often undergo costly processing before it is suitable for human consumption, Customs does not consider such processing to result in a "substantial transformation" unless it changes the character of the API. The necessary analysis is very fact-sensitive, requiring the advice of counsel in collaboration with personnel who understand the specifics of the drug's manufacture.

3. Changes in API suppliers often require a change in product marking

Pharmaceutical companies sometimes change API suppliers to take advantage of lower prices and other business benefits. However, if the country of the API supplier changes, the proper COO marking for the finished product usually changes as well (see No. 2 above). Manufacturers also occasionally purchase the same API from multiple suppliers in different countries. As a result, the correct marking for a drug may vary over time, or from batch to batch. Despite the substantial logistical challenges involved, Customs requires each product, in the form it arrives to the "ultimate purchaser," to be marked with its actual COO.

4. NAFTA employs its own COO marking standard

For goods from NAFTA countries (United States, Canada and Mexico), the COO for Customs-marking purposes is determined under special NAFTA Marking Rules—not the substantial transformation test. Application of the NAFTA Marking Rules can be complex, but generally, where a drug is manufactured with materials from various countries, the COO will be a NAFTA country if all of the "foreign materials" incorporated in the drug (i.e., materials from non-NAFTA countries) undergo an applicable change in tariff classification. For example, if the tariff classification for API made in Germany emerges from processing in Mexico as a finished product with a different classification, a tariff shift has occurred that may render the drug a product of Mexico, assuming other applicable requirements are met.

5. Manufacturers of mismarked products are subject to high penalties

Customs can penalize a company that fails to mark its products with the correct COO, with duties equal to 10 percent of the appraised value of the finished products. Unlike penalties for most Customs violations, these penalties cannot be mitigated by filing a "prior disclosure" of the violation to Customs. It is crucial, therefore, that manufacturers ensure their products are properly marked.

6. The FDA requirement to label drugs with the manufacturer's place of business is not a requirement to list the product's COO

The FDA requires each drug label to "bear conspicuously the name and place of business of the manufacturer, packer, or distributor." The "place" identified for this purpose may or may not be in the same country as the COO marked for Customs purposes. For example, the FDA defines a "manufacturer" as one who performs mixing, granulating, milling, molding, lyophilizing, tableting, encapsulating, coating, or sterilizing, as well as filling dispensing containers with aerosol or gas drugs. Thus, if a drug is manufactured into tablets in the United States, using API from India that is not substantially transformed in the United States, the label may include a "Product of India" marking for Customs purposes and a U.S. "principal place of business" for FDA purposes. It is important to note that a drug may be deemed "misbranded" if "its labeling is false or misleading in any particular," and this includes representations about the product's COO.

7. When selling drugs to the U.S. government, a different COO standard may apply

The substantial transformation test is used under the Trade Agreements Act ("TAA") to determine whether a product is eligible for government procurement by virtue of being either U.S.-made or made in certain designated countries (China and India, for example, are not designated countries). However, the substantial transformation test does not apply to supply contracts for drugs valued below $202,000. Such contracts are subject to the Buy American Act ("BAA"), which gives preferences to products manufactured in the United States, using its own COO standard. Specifically, a drug is BAA-compliant when the cost of the components manufactured in the United States exceeds 50 percent of the cost of all its components.

8. Failure to comply with the TAA and BAA carries severe consequences

If a pharmaceutical company supplies drugs to the federal government and falsely represents them as TAA- or BAA-compliant, it faces not only the loss of a lucrative supply contract, but also the troubling prospect of penalties under the False Claims Act, suspension and debarment, and even criminal charges.

9. Drugs should not be marked "Made in USA" unless they are entirely U.S.-made

When a drug is U.S.-made under the substantial transformation test, the manufacturer may be eager to emphasize the drug's U.S. origin on the packaging or marketing materials. However, a higher standard applies for "Made in the USA" claims and similar statements. Under U.S. consumer protection laws administered by the FTC, only a product that is "all or virtually all" made in the United States may be accompanied by express or implied representations that the product is U.S.-made. CBP only requires a drug to be marked with its COO when it is foreign-made. Therefore, drugs that are substantially transformed in the United States, but that are not "all or virtually all" U.S.-made, can comply with both standards if they simply omit a COO marking.

10. When exporting drugs, "certificates of origin" requested by foreign trading partners are subject to various COO standards

When pharmaceutical companies export their drugs, they often receive requests from foreign importers and customs authorities to provide a "certificate of origin"—usually to prove eligibility for preferential tariff treatment under a free trade agreement ("FTA"). Unfortunately, there is no uniform COO standard in this context. Where an FTA controls, different standards for various category of goods have been negotiated by the signatory countries. Where no FTA applies, the country of export may have its own COO standard. For example, many countries will accept a "U.S. certificate of origin" if at least 50 percent of the product's production costs originate in the United States.

Pharmaceutical companies are especially vulnerable to making non-compliant COO determinations for several reasons. First, drug manufacturers are typically subject to the full range of regulatory regimes discussed above, creating a greater risk of error in applying the numerous divergent standards. Second, it is common for pharmaceutical manufacturers to purchase API from multiple sources in different countries, or to switch API suppliers with some frequency, which can make the COO something of a "moving target." It is vitally important, therefore, that pharmaceutical companies take a fresh look at the COO determinations they have made in the past and verify that their current determinations are correct and accurately reflected in the labeling, packaging, and marketing materials. Finally, companies must ensure that their compliance programs incorporate procedures that ensure the appropriate standards are applied, that they are applied correctly, and that they are applied on an ongoing basis to account for changes in the supply chain.

White Paper 2014-030

This article is presented for informational purposes only and is not intended to constitute legal advice.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement

    Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of www.mondaq.com

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at enquiries@mondaq.com.

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions